The latest updates on EMA product registrations in the last week include:
There are now a significant number of Stelara biosimilars in the market, and competition is likely to be fierce throughout Europe as more tenders are released. It will be interesting to see how prices will stablise as this happenes, and how Stelara pricing will evolve in response.
Two new treatments related to Covid-19. One interesting point is this is the first authorised product for Arcturus Therapeautics. This company has an inhaled mRNA technology product for cystic fibrosis in development, that received orphan designation in February 2024.
There's a trend for launching more Pre-filled Pens, and Wezenla is the latest to add this presentation. Omvoh has added a patient orientated multidose, multistrength option to it's authorised presentations.
Shortages - No changes to the official EU shortages published in the last week.
pharma footpath
